 Sharon Graw
Concepts (298)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 20 | 2025 | 334 | 2.290 |
Why?
| | Arrhythmias, Cardiac | 9 | 2025 | 328 | 0.890 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 6 | 2020 | 57 | 0.760 |
Why?
| | Cardiomyopathies | 5 | 2025 | 325 | 0.720 |
Why?
| | Filamins | 4 | 2025 | 27 | 0.700 |
Why?
| | Death, Sudden, Cardiac | 7 | 2025 | 187 | 0.650 |
Why?
| | Ventricular Function, Left | 5 | 2025 | 502 | 0.620 |
Why?
| | Connectin | 6 | 2025 | 35 | 0.560 |
Why?
| | Phenotype | 16 | 2025 | 3143 | 0.490 |
Why?
| | Genes, BRCA1 | 2 | 2005 | 41 | 0.430 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2025 | 197 | 0.410 |
Why?
| | Electrocardiography | 6 | 2025 | 610 | 0.410 |
Why?
| | Glycogen Storage Disease Type IIb | 3 | 2025 | 24 | 0.410 |
Why?
| | Ventricular Remodeling | 2 | 2025 | 257 | 0.390 |
Why?
| | Heart Failure | 7 | 2025 | 2065 | 0.330 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 6 | 2016 | 98 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2362 | 0.300 |
Why?
| | Heart Ventricles | 4 | 2025 | 745 | 0.300 |
Why?
| | Founder Effect | 2 | 2005 | 11 | 0.290 |
Why?
| | Receptors, Nicotinic | 4 | 2012 | 344 | 0.280 |
Why?
| | Genetic Testing | 8 | 2025 | 453 | 0.280 |
Why?
| | Sequence Deletion | 3 | 2014 | 184 | 0.270 |
Why?
| | Myocardium | 5 | 2020 | 921 | 0.260 |
Why?
| | Stroke Volume | 6 | 2025 | 584 | 0.260 |
Why?
| | Mutation | 10 | 2020 | 3984 | 0.250 |
Why?
| | DNA Mutational Analysis | 7 | 2018 | 397 | 0.230 |
Why?
| | Genetic Variation | 4 | 2021 | 990 | 0.230 |
Why?
| | Genetic Diseases, Inborn | 1 | 2025 | 45 | 0.230 |
Why?
| | Jews | 1 | 2005 | 24 | 0.230 |
Why?
| | Nanotubes, Carbon | 1 | 2025 | 48 | 0.220 |
Why?
| | Rare Diseases | 1 | 2025 | 108 | 0.220 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2025 | 119 | 0.220 |
Why?
| | Muscle Proteins | 3 | 2025 | 239 | 0.210 |
Why?
| | Middle Aged | 25 | 2025 | 33782 | 0.210 |
Why?
| | Mutation, Missense | 3 | 2015 | 335 | 0.210 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2000 | 34 | 0.200 |
Why?
| | Heart Rate | 2 | 2025 | 801 | 0.200 |
Why?
| | Female | 39 | 2025 | 74016 | 0.200 |
Why?
| | Germ-Line Mutation | 1 | 2003 | 170 | 0.190 |
Why?
| | Male | 35 | 2025 | 68250 | 0.190 |
Why?
| | Prognosis | 7 | 2025 | 3995 | 0.180 |
Why?
| | Breast Neoplasms | 2 | 2005 | 2283 | 0.180 |
Why?
| | Adult | 24 | 2025 | 38393 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2022 | 40 | 0.180 |
Why?
| | Humans | 48 | 2025 | 138972 | 0.170 |
Why?
| | Biocompatible Materials | 1 | 2025 | 426 | 0.170 |
Why?
| | Tissue Engineering | 1 | 2025 | 426 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2016 | 140 | 0.160 |
Why?
| | Physical Chromosome Mapping | 1 | 2000 | 20 | 0.160 |
Why?
| | Chromosome Breakage | 1 | 2000 | 23 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 466 | 0.160 |
Why?
| | Chromosome Inversion | 1 | 2000 | 18 | 0.160 |
Why?
| | Pedigree | 8 | 2015 | 510 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2021 | 168 | 0.160 |
Why?
| | Protein Kinases | 2 | 2012 | 308 | 0.160 |
Why?
| | Ankyrins | 1 | 2019 | 12 | 0.160 |
Why?
| | Echocardiography | 4 | 2025 | 638 | 0.150 |
Why?
| | Genotype | 5 | 2022 | 1849 | 0.150 |
Why?
| | Mice, Inbred C3H | 3 | 2016 | 270 | 0.150 |
Why?
| | Recombination, Genetic | 1 | 2000 | 206 | 0.150 |
Why?
| | Cardiovascular Agents | 2 | 2025 | 156 | 0.150 |
Why?
| | Hippocampus | 2 | 2016 | 929 | 0.150 |
Why?
| | Abnormalities, Multiple | 1 | 2000 | 195 | 0.140 |
Why?
| | Hydrogels | 1 | 2025 | 680 | 0.140 |
Why?
| | Disease Management | 3 | 2021 | 621 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 197 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2003 | 573 | 0.130 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 4 | 0.130 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 25 | 0.130 |
Why?
| | Marfan Syndrome | 1 | 2017 | 41 | 0.130 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 278 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.130 |
Why?
| | Internationality | 1 | 2017 | 158 | 0.130 |
Why?
| | Transcriptome | 2 | 2020 | 966 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2025 | 15901 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2021 | 403 | 0.120 |
Why?
| | Registries | 6 | 2025 | 2081 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 527 | 0.120 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2017 | 136 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 430 | 0.110 |
Why?
| | Desmosomes | 1 | 2014 | 21 | 0.110 |
Why?
| | Spain | 2 | 2005 | 45 | 0.110 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 21 | 0.110 |
Why?
| | Base Sequence | 5 | 2014 | 2176 | 0.110 |
Why?
| | Long-Term Potentiation | 1 | 2016 | 199 | 0.110 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 49 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 193 | 0.100 |
Why?
| | Exons | 3 | 2025 | 352 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2014 | 164 | 0.100 |
Why?
| | Risk Assessment | 4 | 2025 | 3466 | 0.090 |
Why?
| | Heterozygote | 3 | 2025 | 306 | 0.090 |
Why?
| | Genes, Duplicate | 1 | 2011 | 4 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 429 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1746 | 0.090 |
Why?
| | Colorado | 4 | 2017 | 4543 | 0.090 |
Why?
| | Schizophrenia | 3 | 2012 | 451 | 0.090 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2025 | 56 | 0.090 |
Why?
| | Neural Inhibition | 1 | 2012 | 177 | 0.080 |
Why?
| | Aged | 8 | 2025 | 24172 | 0.080 |
Why?
| | Age of Onset | 2 | 2025 | 521 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 897 | 0.080 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2925 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2025 | 543 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 92 | 0.070 |
Why?
| | Time Factors | 4 | 2025 | 6869 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 5801 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1441 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 4095 | 0.070 |
Why?
| | Desmin | 1 | 2007 | 23 | 0.070 |
Why?
| | Sequence Analysis, DNA | 2 | 2025 | 824 | 0.070 |
Why?
| | Young Adult | 5 | 2025 | 13371 | 0.070 |
Why?
| | Genetic Association Studies | 2 | 2021 | 373 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1235 | 0.070 |
Why?
| | Cloning, Molecular | 3 | 2011 | 533 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2138 | 0.060 |
Why?
| | DNA Methylation | 1 | 2011 | 636 | 0.060 |
Why?
| | Lamin Type A | 2 | 2022 | 45 | 0.060 |
Why?
| | Neurons | 1 | 2015 | 1602 | 0.060 |
Why?
| | Risk Factors | 4 | 2025 | 10385 | 0.060 |
Why?
| | Ventricular Myosins | 1 | 2005 | 30 | 0.060 |
Why?
| | Syndrome | 2 | 2011 | 377 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5152 | 0.060 |
Why?
| | Animals | 11 | 2025 | 37243 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1471 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 36 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2019 | 3029 | 0.060 |
Why?
| | Injections | 1 | 2025 | 190 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 163 | 0.050 |
Why?
| | Introns | 1 | 2025 | 254 | 0.050 |
Why?
| | Myocytes, Cardiac | 2 | 2025 | 513 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2005 | 177 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 149 | 0.050 |
Why?
| | Aortic Diseases | 1 | 2025 | 119 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2015 | 704 | 0.050 |
Why?
| | Particle Size | 1 | 2025 | 391 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 55 | 0.050 |
Why?
| | Materials Testing | 1 | 2025 | 350 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2025 | 228 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2003 | 30 | 0.050 |
Why?
| | Karyotyping | 2 | 2000 | 103 | 0.050 |
Why?
| | Haplotypes | 1 | 2005 | 497 | 0.050 |
Why?
| | Disease Progression | 2 | 2025 | 2752 | 0.050 |
Why?
| | Genome, Human | 1 | 2025 | 418 | 0.050 |
Why?
| | DNA, Neoplasm | 1 | 2003 | 158 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2019 | 5530 | 0.050 |
Why?
| | Chromosome Mapping | 5 | 2009 | 505 | 0.050 |
Why?
| | Brain | 1 | 2015 | 2791 | 0.050 |
Why?
| | Chromosomes, Human, Pair 15 | 2 | 2015 | 54 | 0.050 |
Why?
| | Mice | 5 | 2025 | 17828 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 248 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 172 | 0.050 |
Why?
| | Temperature | 1 | 2025 | 660 | 0.050 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 2 | 2014 | 29 | 0.040 |
Why?
| | Atrial Fibrillation | 1 | 2025 | 377 | 0.040 |
Why?
| | Microarray Analysis | 1 | 2021 | 116 | 0.040 |
Why?
| | Cell Line | 3 | 2009 | 2879 | 0.040 |
Why?
| | Chromosomes | 1 | 2021 | 105 | 0.040 |
Why?
| | Cohort Studies | 3 | 2020 | 5744 | 0.040 |
Why?
| | Adolescent | 6 | 2025 | 21581 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2021 | 159 | 0.040 |
Why?
| | Cricetinae | 2 | 2000 | 297 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 179 | 0.040 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2591 | 0.040 |
Why?
| | Terminal Repeat Sequences | 1 | 2000 | 18 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1949 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2018 | 3574 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2000 | 114 | 0.040 |
Why?
| | New Mexico | 1 | 2000 | 94 | 0.040 |
Why?
| | Alu Elements | 1 | 2000 | 28 | 0.040 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2000 | 32 | 0.040 |
Why?
| | Maleimides | 1 | 2019 | 21 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2020 | 2815 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 193 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2005 | 1149 | 0.040 |
Why?
| | Transfection | 3 | 2011 | 942 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2050 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 165 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 10921 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 268 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 609 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1235 | 0.040 |
Why?
| | Alleles | 1 | 2021 | 890 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2021 | 513 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 517 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1473 | 0.040 |
Why?
| | Child | 4 | 2025 | 21936 | 0.030 |
Why?
| | Family Health | 2 | 2011 | 195 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2850 | 0.030 |
Why?
| | Family | 2 | 2014 | 680 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 459 | 0.030 |
Why?
| | HeLa Cells | 2 | 2011 | 638 | 0.030 |
Why?
| | Fibrosis | 1 | 2020 | 539 | 0.030 |
Why?
| | beta Catenin | 1 | 2019 | 253 | 0.030 |
Why?
| | Europe | 1 | 2018 | 407 | 0.030 |
Why?
| | Aneurysm, False | 1 | 2017 | 45 | 0.030 |
Why?
| | Neck | 1 | 2017 | 104 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 411 | 0.030 |
Why?
| | Heredity | 1 | 2015 | 11 | 0.030 |
Why?
| | Sensory Gating | 1 | 2016 | 47 | 0.030 |
Why?
| | Head | 1 | 2017 | 115 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 130 | 0.030 |
Why?
| | Italy | 1 | 2015 | 109 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4316 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 202 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1994 | 4 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2745 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 581 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 65 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2016 | 318 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2011 | 289 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 501 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1994 | 114 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 1994 | 1047 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1993 | 39 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2011 | 3397 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1730 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 321 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 433 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1084 | 0.030 |
Why?
| | Heart | 1 | 2017 | 612 | 0.020 |
Why?
| | Action Potentials | 1 | 2016 | 485 | 0.020 |
Why?
| | United States | 3 | 2018 | 15074 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2000 | 850 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1497 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 74 | 0.020 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 86 | 0.020 |
Why?
| | Penetrance | 1 | 2011 | 28 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2000 | 6158 | 0.020 |
Why?
| | Bungarotoxins | 1 | 2011 | 47 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 382 | 0.020 |
Why?
| | Xenopus laevis | 1 | 2011 | 107 | 0.020 |
Why?
| | Allosteric Regulation | 1 | 2011 | 93 | 0.020 |
Why?
| | Isoxazoles | 1 | 2011 | 53 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2011 | 58 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 171 | 0.020 |
Why?
| | Organ Specificity | 1 | 2011 | 310 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 650 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2093 | 0.020 |
Why?
| | Multigene Family | 1 | 2011 | 200 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2030 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2011 | 95 | 0.020 |
Why?
| | Point Mutation | 1 | 2011 | 238 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2011 | 291 | 0.020 |
Why?
| | Oocytes | 1 | 2011 | 179 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 421 | 0.020 |
Why?
| | Autistic Disorder | 1 | 2012 | 206 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 666 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 984 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 707 | 0.020 |
Why?
| | RNA | 2 | 2011 | 925 | 0.020 |
Why?
| | Child, Preschool | 2 | 2000 | 11158 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 258 | 0.020 |
Why?
| | Epilepsy | 1 | 2012 | 335 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2849 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 30 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2159 | 0.020 |
Why?
| | Genes, Dominant | 1 | 2007 | 97 | 0.020 |
Why?
| | Cognition | 1 | 2015 | 1179 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 644 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2012 | 766 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5092 | 0.020 |
Why?
| | Mental Disorders | 1 | 2015 | 1095 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7661 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 413 | 0.010 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 72 | 0.010 |
Why?
| | Sarcomeres | 1 | 2005 | 93 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2233 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2005 | 236 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2005 | 397 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 449 | 0.010 |
Why?
| | Smoking | 1 | 2011 | 1610 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 862 | 0.010 |
Why?
| | DNA Primers | 2 | 1994 | 509 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 365 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2009 | 1391 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1487 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2007 | 4182 | 0.010 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1981 | 3 | 0.010 |
Why?
| | Carbon-Nitrogen Ligases | 1 | 1981 | 5 | 0.010 |
Why?
| | Ligases | 1 | 1981 | 32 | 0.010 |
Why?
| | Rats | 1 | 2007 | 5591 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2005 | 1734 | 0.010 |
Why?
| | Muridae | 1 | 1994 | 5 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 1994 | 24 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1994 | 133 | 0.010 |
Why?
| | Cosmids | 1 | 1993 | 6 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1993 | 75 | 0.010 |
Why?
| | Genetic Markers | 1 | 1994 | 344 | 0.010 |
Why?
| | Infant | 1 | 2007 | 9577 | 0.010 |
Why?
| | Genome | 1 | 1994 | 299 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 48 | 0.000 |
Why?
| | Genetic Complementation Test | 1 | 1981 | 66 | 0.000 |
Why?
| | Cell Fusion | 1 | 1981 | 50 | 0.000 |
Why?
| | Cricetulus | 1 | 1981 | 110 | 0.000 |
Why?
| | Purines | 1 | 1981 | 179 | 0.000 |
Why?
| | Ovary | 1 | 1981 | 223 | 0.000 |
Why?
| | Lymphocytes | 1 | 1981 | 395 | 0.000 |
Why?
| | Fibroblasts | 1 | 1981 | 1002 | 0.000 |
Why?
|
|
Graw's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|